S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
All the trading advice you’ve ever received boils down to this (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
All the trading advice you’ve ever received boils down to this (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
All the trading advice you’ve ever received boils down to this (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
All the trading advice you’ve ever received boils down to this (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
All the trading advice you’ve ever received boils down to this (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
All the trading advice you’ve ever received boils down to this (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
All the trading advice you’ve ever received boils down to this (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
All the trading advice you’ve ever received boils down to this (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Telix Pharmaceuticals Stock Price, News & Analysis (ASX:TLX)

Compare
Today's Range
N/A
50-Day Range
A$41.24
▼
A$49.92
52-Week Range
N/A
Volume
746,789 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

TLX stock logo

About Telix Pharmaceuticals Stock (ASX:TLX)

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.


TLX Stock News Headlines

December 4, 2023 | finance.yahoo.com
First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent
November 29, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS
December 6, 2023 | Financial Alphas (Ad)
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
November 29, 2023 | finance.yahoo.com
Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS
November 22, 2023 | fool.com.au
Could buying these ASX shares at $9 now be like investing in Tesla in 2010?
November 14, 2023 | finance.yahoo.com
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
November 13, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
November 13, 2023 | finance.yahoo.com
Mauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologic Surgery
December 6, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
November 13, 2023 | finance.yahoo.com
Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery
November 8, 2023 | finance.yahoo.com
Telix to Present at Jefferies London Healthcare Conference 2023
October 19, 2023 | fool.com.au
Telix Pharmaceuticals share price sinks 12% despite rocketing revenue
October 18, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability
October 18, 2023 | finance.yahoo.com
Telix reports fourth consecutive quarter of positive operating cash flow
October 17, 2023 | msn.com
Global biotech sector set to boom but where are Aussie investors?
September 19, 2023 | fool.com.au
Who wants to be a millionaire? 3 ASX shares I think that could make it happen
September 19, 2023 | fool.com.au
Who wants to be a millionaire? 3 ASX shares I think could make it happen
August 24, 2023 | fool.com.au
ASX 200 healthcare stock Telix Pharmaceuticals surges 12% on ‘excellent result’
August 23, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: Telix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage Company
July 19, 2023 | fool.com.au
Why is the Telix share price crashing 17% today?
July 19, 2023 | finance.yahoo.com
Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow
June 26, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC
June 22, 2023 | reuters.com
Australia's Telix Pharma hits record high after buying UK medical devices firm
June 22, 2023 | finance.yahoo.com
Telix to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI
June 21, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical
June 21, 2023 | finance.yahoo.com
Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint Medical
June 20, 2023 | finanznachrichten.de
Telix Pharmaceuticals Limited: Telix Urology Innovation Showcase to be held at The Yale Club, New York City
See More Headlines
Receive TLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
ASX:TLX
CUSIP
N/A
CIK
N/A
Web
www.telixpharma.com
Phone
61 4 4914 8448
Fax
N/A
Employees
234
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.33)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-47,510,000.00
Net Margins
-13.31%
Pretax Margin
N/A
Return on Equity
-52.36%
Return on Assets
5.18%

Debt

Debt-to-Equity Ratio
17.23
Current Ratio
1.54
Quick Ratio
3.00

Sales & Book Value

Annual Sales
$356.88 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
8.35
Book Value
A$0.24 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
323,400,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
2.42
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Christian P. Behrenbruch BEng(Hons) (Age 48)
    DPhil(Oxon), GAICD, J.D., M.B.A., MBA, Co-Founder, MD, Group CEO & Executive Director
    Comp: $599.23k
  • Mr. Darren Smith B.Bus. (Age 58)
    FCPA, M.B.A., Group Chief Financial Officer
    Comp: $245.86k
  • Dr. Andreas Kluge M.D.
    Ph.D., Chief Medical Advisor & Director (Leave of Absence)
  • Dr. Colin Hayward FFPM
    MBBS, Group Chief Medical Officer
  • Mr. Richard Valeix M.B.A.
    Group Chief Commercial Officer
  • Dr. Michael Wheatcroft B.Sc.
    BSc(Hons), Ph.D., Ph.D., (Cantab), Chief Scientist
  • Mr. Craig Ulrick
    Chief Information Officer
  • Ms. Kyahn Williamson B.A.
    Senior Vice President of Corporate Communications & Investor Relations
  • Ms. Melanie Farris (AGIA
    ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C., Senior VP of Global Governance, Risk & Compliance
  • Ms. Lena Moran-Adams L.L.B.
    General Counsel

Key Competitors

View All Competitors

Insiders















TLX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Telix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Telix Pharmaceuticals investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS).

This page (ASX:TLX) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -